We are live on ! Find out more
RPRX icon

Royalty Pharma
RPRX

378 hedge funds and large institutions have $8.35B invested in Royalty Pharma in 2024 Q2 according to their latest regulatory filings, with 60 funds opening new positions, 141 increasing their positions, 127 reducing their positions, and 56 closing their positions.

New
Increased
Maintained
Reduced
Closed

222% more call options, than puts

Call options by funds: $13.5M | Put options by funds: $4.19M

11% more repeat investments, than reductions

Existing positions increased: 141 | Existing positions reduced: 127

1.94% more ownership

Funds ownership: 68.15% → 70.09% (+1.9%)

7% more first-time investments, than exits

New positions opened: 60 | Existing positions closed: 56

0% more funds holding

Funds holding: 378 → 378 (0)

0% more funds holding in top 10

Funds holding in top 10: 7 → 7 (0)

10% less capital invested

Capital invested by funds: $9.24B → $8.35B (-$885M)

Holders
378
Holders Change
–
Holders Change %
0%
% of All Funds
5.46%
Holding in Top 10
7
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.1%
New
60
Increased
141
Reduced
127
Closed
56
Calls
$13.5M
Puts
$4.19M
Net Calls
+$9.31M
Net Calls Change
+$4.69M

Top Buyers

1
Swedbank
Swedbank
Sweden
+$300M
2
BlackRock
BlackRock
New York
+$50.2M
3
BGIM
Brandywine Global Investment Management
Pennsylvania
+$45.4M
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$29.5M
5
Invesco
Invesco
Georgia
+$29.5M

Top Sellers

1
Fidelity Investments
Fidelity Investments
Massachusetts
-$159M
2
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance)
Ontario, Canada
-$81.4M
3
Millennium Management
Millennium Management
New York
-$64.2M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
-$15.8M
5
CSS
Cubist Systematic Strategies
Connecticut
-$14.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
AB
151
Amalgamated Bank
New York
$1.81M +$1.32M +47,632 +228%
FAFTFSNP
152
Fjarde AP-fonden (The Fourth Swedish National Pensionfund)
Sweden
$1.79M +$1.89M +68,050 New
KWM
153
Kingsview Wealth Management
Oregon
$1.77M +$1.86M +67,145 New
PCMU
154
Paragon Capital Management (Utah)
Utah
$1.73M +$1.82M +65,643 New
URS
155
Utah Retirement Systems
Utah
$1.7M +$13.9K +500 +0.8%
IMRF
156
Illinois Municipal Retirement Fund
Illinois
$1.68M – – –
SOADOR
157
State of Alaska Department of Revenue
Alaska
$1.67M – – –
PAM
158
Panagora Asset Management
Massachusetts
$1.66M -$3.59M -129,378 -67%
AWM
159
AE Wealth Management
Kansas
$1.66M +$1.75M +62,998 New
CCIA
160
Campbell & Co Investment Adviser
Maryland
$1.62M +$1.02M +36,807 +150%
American Century Companies
161
American Century Companies
Missouri
$1.59M +$193K +6,955 +13%
AA
162
AlphaCentric Advisors
Puerto Rico
$1.58M – – –
SC
163
Searle & Co
Connecticut
$1.52M +$1.59M +57,500 New
Wellington Management Group
164
Wellington Management Group
Massachusetts
$1.51M +$20.6K +743 +1%
EB
165
Eastern Bank
Massachusetts
$1.49M -$11.5K -414 -0.7%
SAM
166
Simplify Asset Management
Nevada
$1.48M -$2.56M -92,267 -62%
VOYA Investment Management
167
VOYA Investment Management
Georgia
$1.45M +$293K +10,573 +24%
CUAMC
168
China Universal Asset Management Company
China
$1.4M -$912K -32,895 -38%
SLAM
169
Swiss Life Asset Management
$1.38M +$1.45M +52,227 New
ASN
170
Advisory Services Network
Georgia
$1.38M +$1.45M +52,219 New
PP
171
PDT Partners
New York
$1.36M +$1.43M +51,436 New
AI
172
Atria Investments
North Carolina
$1.34M +$327K +11,803 +30%
EGM
173
Engineers Gate Manager
New York
$1.33M -$569K -20,524 -29%
BPCE
174
Bank Pictet & Cie (Europe)
Germany
$1.32M – – –
AIC
175
Aurora Investment Counsel
Georgia
$1.32M +$181K +6,544 +15%
5 6
7
8 9

RPRX Hedge Fund Activity: Q2 2024 in Review

378 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Royalty Pharma (RPRX) for Q2 2024, worth a combined $8.35B — down 9.6% from $9.24B a quarter earlier.

Buyers outnumbered sellers: 60 funds opened new RPRX positions and 56 closed out — a net gain of 4 holders — while 141 added to existing stakes and 127 trimmed.

The largest buyer was Swedbank, opening a new position worth an estimated $300M. The largest seller was Fidelity Investments, cutting an estimated $159M.

  • 378 institutional investors held Royalty Pharma (RPRX) as of Q2 2024, unchanged from Q1 2024.
  • Funds reported $8.35B of Royalty Pharma stock for Q2 2024, down 9.6% quarter-over-quarter.
  • 60 funds opened new Royalty Pharma positions in Q2 2024 and 56 closed out, a net change of +4 holders.
  • The largest Royalty Pharma buyer in Q2 2024 was Swedbank, an estimated $300M added.
  • The largest Royalty Pharma seller in Q2 2024 was Fidelity Investments, an estimated $159M sold.

Based on aggregated 13F filings for Q2 2024.